KALARIS THERAPEUTICS, INC. Operating Lease, Expense
KALARIS THERAPEUTICS, INC. (KLRS) reported Operating Lease, Expense of $2.60 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-02
- KALARIS THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-09-30 was $2.60M, a 116.67% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-06-30 was $2.60M, a 100.00% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-03-31 was $2.60M, a 62.50% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating lease, expense for the quarter ending 2022-12-31 was $2.50M, a 38.89% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $6.60M, a 6.45% increase from fiscal 2021.
- KALARIS THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $6.20M, a 55.00% increase from fiscal 2020.
- KALARIS THERAPEUTICS, INC. operating lease, expense for fiscal 2020 was $4.00M, a 90.48% increase from fiscal 2019.
- KALARIS THERAPEUTICS, INC. operating lease, expense for fiscal 2019 was $2.10M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2023-09-30 | $2.60M 10-Q · filed 2023-11-02 | $5.20M derived: sum of 2 quarters · filed 2023-11-02 | $7.70M 10-Q · filed 2023-11-02 | $10.30M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2023-06-30 | $2.60M 10-Q · filed 2023-08-03 | $5.10M 10-Q · filed 2023-08-03 | $7.70M derived: sum of 3 quarters · filed 2023-08-03 | $8.90M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2023-03-31 | $2.60M 10-Q · filed 2023-05-04 | $5.10M derived: sum of 2 quarters · filed 2023-05-04 | $6.30M derived: sum of 3 quarters · filed 2023-11-02 | $7.60M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $3.70M derived: sum of 2 quarters · filed 2023-11-02 | $5.00M derived: sum of 3 quarters · filed 2023-11-02 | $6.60M 10-K · filed 2023-02-15 | |||
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-02 | $2.50M derived: sum of 2 quarters · filed 2023-11-02 | $4.10M 10-Q · filed 2023-11-02 | $5.90M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-03 | $2.80M 10-Q · filed 2023-08-03 | $4.70M derived: sum of 3 quarters · filed 2023-08-03 | $6.70M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $1.60M 10-Q · filed 2023-05-04 | $3.40M derived: sum of 2 quarters · filed 2023-05-04 | $5.40M derived: sum of 3 quarters · filed 2023-05-04 | $6.70M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $3.80M derived: sum of 2 quarters · filed 2023-02-15 | $5.10M derived: sum of 3 quarters · filed 2023-02-15 | $6.20M 10-K · filed 2023-02-15 | |||
| 2021-09-30 | $2.00M 10-Q · filed 2022-11-03 | $3.30M derived: sum of 2 quarters · filed 2022-11-03 | $4.40M 10-Q · filed 2022-11-03 | $5.90M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $1.30M 10-Q · filed 2022-08-04 | $2.50M 10-Q · filed 2022-08-04 | $3.90M derived: sum of 3 quarters · filed 2022-08-04 | $4.80M derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $1.30M 10-Q · filed 2022-05-05 | $2.60M derived: sum of 2 quarters · filed 2022-05-05 | $3.50M derived: sum of 3 quarters · filed 2022-05-05 | $4.40M derived: sum of 4 quarters · filed 2022-05-05 | |||
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $2.20M derived: sum of 2 quarters · filed 2022-02-10 | $3.10M derived: sum of 3 quarters · filed 2022-02-10 | $4.00M 10-K · filed 2022-02-10 | |||
| 2020-09-30 | $900.00K 10-Q · filed 2021-11-05 | $1.00M 10-Q · filed 2020-11-10 | $1.80M derived: sum of 2 quarters · filed 2021-11-05 | $2.70M 10-Q · filed 2021-11-05 | $3.00M 10-Q · filed 2020-11-10 | $3.80M derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | $900.00K 10-Q · filed 2021-08-06 | $1.00M 10-Q · filed 2020-09-02 | $1.80M 10-Q · filed 2021-08-06 | $2.00M 10-Q · filed 2020-09-02 | $2.90M derived: sum of 3 quarters · filed 2021-08-06 | $3.50M derived: sum of 4 quarters · filed 2021-08-06 | |
| 2020-03-31 | $1.00M 10-Q · filed 2021-05-06 | $2.00M derived: sum of 2 quarters · filed 2021-05-06 | $2.60M derived: sum of 3 quarters · filed 2021-05-06 | $2.70M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.60M derived: sum of 2 quarters · filed 2021-02-12 | $1.70M derived: sum of 3 quarters · filed 2021-02-12 | $2.10M 10-K · filed 2021-02-12 | |||
| 2019-09-30 | $600.00K 10-Q · filed 2020-11-10 | $700.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.10M 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | $100.00K 10-Q · filed 2020-09-02 | $500.00K 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |